Product Code: ETC069943 | Publication Date: Jun 2023 | Updated Date: Jan 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The India biosimilar market is expected to grow at a CAGR of 24.5% during the forecast period from 2020 to 2027, due to increasing government support and initiatives such as Make in India program and Drug Pricing Control Order (DPCO). This has enabled increased access for drugs at low cost and improved affordability among consumers across the country. The rising prevalence of chronic diseases such as cancer, diabetes, rheumatoid arthritis and others are driving growth in the market. Additionally, technological advancements related to biologics development have facilitated greater acceptance among medical professionals for using biosimilars instead of branded products or generic medicines.
Increasing Prevalence Of Chronic Diseases: The rising prevalence of chronic conditions is fueling demand for more effective treatment solutions, which is boosting the adoption rate of biological therapies including monoclonal antibody-based therapeutics (mAb), recombinant proteins/antibodies (rPAb), peptides/small molecules etc., thereby providing an impetus for growth in this sector. Government Incentives And Regulatory Support: Various government schemes like Pradhan Mantri Jan Aushadhi Yojana (PMJAY) have been launched to provide affordable healthcare services by enabling access to quality medicines at lower prices through public distribution systems such as Jan Aushadi stores ? these also include various kinds of biologicals including biosimilars. Additionally, regulatory authorities like Central Drugs Standard Control Organization (CDSCO) have introduced certain guidelines that help simplify product registration processes while promoting innovation within this space so that manufacturers can make high-quality yet cost-effective products available in the market without compromising safety standards or efficacy parameters.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Biosimilars Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Biosimilars Market Revenues & Volume, 2020 & 2027F |
3.3 India Biosimilars Market - Industry Life Cycle |
3.4 India Biosimilars Market - Porter's Five Forces |
3.5 India Biosimilars Market Revenues & Volume Share, By Product, 2020 & 2027F |
3.6 India Biosimilars Market Revenues & Volume Share, By Indication, 2020 & 2027F |
3.7 India Biosimilars Market Revenues & Volume Share, By Manufacturing, 2020 & 2027F |
4 India Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 India Biosimilars Market Trends |
6 India Biosimilars Market, By Types |
6.1 India Biosimilars Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 India Biosimilars Market Revenues & Volume, By Product, 2018 - 2027F |
6.1.3 India Biosimilars Market Revenues & Volume, By Insulin, 2018 - 2027F |
6.1.4 India Biosimilars Market Revenues & Volume, By Follitropin, 2018 - 2027F |
6.1.5 India Biosimilars Market Revenues & Volume, By Calcitonin, 2018 - 2027F |
6.1.6 India Biosimilars Market Revenues & Volume, By Glucagon, 2018 - 2027F |
6.1.7 India Biosimilars Market Revenues & Volume, By Teriparatide, 2018 - 2027F |
6.1.8 India Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F |
6.2 India Biosimilars Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 India Biosimilars Market Revenues & Volume, By Oncology, 2018 - 2027F |
6.2.3 India Biosimilars Market Revenues & Volume, By Offsite Treatment, 2018 - 2027F |
6.2.4 India Biosimilars Market Revenues & Volume, By Chronic Disorders, 2018 - 2027F |
6.2.5 India Biosimilars Market Revenues & Volume, By Blood Disorders, 2018 - 2027F |
6.2.6 India Biosimilars Market Revenues & Volume, By Infectious Diseases, 2018 - 2027F |
6.2.7 India Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F |
6.3 India Biosimilars Market, By Manufacturing |
6.3.1 Overview and Analysis |
6.3.2 India Biosimilars Market Revenues & Volume, By Outsourced, 2018 - 2027F |
6.3.3 India Biosimilars Market Revenues & Volume, By In-house, 2018 - 2027F |
7 India Biosimilars Market Import-Export Trade Statistics |
7.1 India Biosimilars Market Export to Major Countries |
7.2 India Biosimilars Market Imports from Major Countries |
8 India Biosimilars Market Key Performance Indicators |
9 India Biosimilars Market - Opportunity Assessment |
9.1 India Biosimilars Market Opportunity Assessment, By Product, 2020 & 2027F |
9.2 India Biosimilars Market Opportunity Assessment, By Indication, 2020 & 2027F |
9.3 India Biosimilars Market Opportunity Assessment, By Manufacturing, 2020 & 2027F |
10 India Biosimilars Market - Competitive Landscape |
10.1 India Biosimilars Market Revenue Share, By Companies, 2020 |
10.2 India Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |